Developer · United States
Transcend Therapeutics, Inc.
Transcend Therapeutics is a clinical-stage neuroscience company developing rapid-acting treatments for neuropsychiatric diseases, led by TSND-201 (methylone) for PTSD. Founded in 2021, it became a wholly owned subsidiary of Otsuka America, Inc. when Otsuka Pharmaceutical completed its acquisition in June 2026.
1compound
1program
1indication
Phase 3lead asset
Pipeline (1)
- Post-traumatic stress disorderPhase 3Recruiting
Deals & partnerships
- Jun 12, 2026AcquisitionOtsuka completes acquisition of Transcend TherapeuticsTranscend became a wholly owned subsidiary of Otsuka America, Inc., closing the deal announced 2026-03-27. (Otsuka's own Japan-newsroom disclosure of the same closing is dated 2026-06-15; occurred_on follows the original US closing announcement.)
- Mar 27, 2026AcquisitionOtsuka Pharmaceutical agrees to acquire Transcend Therapeutics for up to $1.225BOtsuka, via subsidiary Otsuka America, Inc., agreed to acquire Transcend Therapeutics: USD 700M upfront to shareholders at closing plus up to USD 525M in sales-milestone contingent consideration (total potential $1.225B), explicitly to accelerate the TSND-201 PTSD program.
Recent activity
- Jun 15, 2026Phase changeMethylone (TSND-201)·Post-traumatic stress disorderPhase 3Otsuka completed acquisition of Transcend Therapeutics; program continues under Otsuka.source ↗
- Apr 2, 2026Phase changeMethylone (TSND-201)·Post-traumatic stress disorderPhase 3Phase 3 EMPOWER-1 (NCT07456696) initiated/recruiting for PTSD.source ↗
- Jul 10, 2025Phase changeMethylone (TSND-201)·Post-traumatic stress disorderPhase 2FDA granted Breakthrough Therapy Designation for TSND-201 in PTSD.source ↗
- Feb 19, 2025Phase changeMethylone (TSND-201)·Post-traumatic stress disorderPhase 1/2IMPACT-1 (NCT05741710) met primary endpoint: placebo-adjusted CAPS-5 -9.64 at Day 64 (p=0.011).source ↗
Trials recruiting · 1 recruiting of 5 sponsored
- Phase 3Methylone (TSND-201)
Phase 3 Evaluation of TSND-201 for the Treatment of PTSD (EMPOWER-1)
Competitive landscape
Other companies developing against Transcend Therapeutics, Inc.'s targets or indications.
- Definium Therapeutics, Inc.2 compoundsSERTPost-traumatic stress disorder
- Otsuka Pharmaceutical Co., Ltd.2 compoundsSERTPost-traumatic stress disorder
- COMPASS Pathways plc1 compoundPost-traumatic stress disorder
- EmpathBio, Inc.1 compoundSERT
- Neuphoria Therapeutics, Inc.1 compoundPost-traumatic stress disorder
- Tonix Pharmaceuticals Holding Corp.1 compoundPost-traumatic stress disorder
